866-997-4948(US-Canada Toll Free)

Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors

Published By :

La Merie Publishing

Published Date : Apr 2015

Category :

Therapeutic Area

No. of Pages : 414 Pages


Competitor Analysis: Therapeutic Antibodies 2015: Biosimilars & Biosuperiors

This Competitive Intelligence Report about Therapeutic Antibodies 2015: Biosimilars & Biosuperiors provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of April 2015.

Total sales of recombinant therapeutic monoclonal antibodies originating from companies located in regulated markets reached US$ 82.2 bln (+8.6% vs previous year) in the year 2014.

The report lists specifically for each target the branded products with their 2014 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development.

The report includes a compilation of currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets:

  • VEGF
  • TNF
  • Her2
  • CD20
  • EGF-R
  • B7.1/B7.2 (CD80/CD86)
  • IL-6R
  • Alpha4/beta1/7 integrin
  • IgE
  • RSV
  • RANKL
  • Complement C5
  • IL-12/IL-23
  • CD52

Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
Table of Contents

1) 2014 Sales of Therapeutic Antibodies
  • Anti-TNF Antibody Sales 2014
  • Cancer Antibody Sales 2014
  • Other Anti-Inflammatory Antibody Sales 2014
  • Ophthalmic Antibody Sales 2014
  • Cardiometabolic & Antiviral Antibody Sales 2014
2) VEGF Antibodies

Marketed VEGF & VEGF-R Antibodies in Oncology:
  • Avastin Sales & Pipeline
  • Zaltrap Sales & Pipeline
  • Cyramza Sales & Pipeline
Avastin & Zaltrap Biosuperiors:
  • Anti-VEGF & Antibody Combination Pipeline
  • Bispecific Anti-VEGF Antibody Pipeline
Cyramza Biosuperiors:
  • Anti-VEGF-R & Antibody Combination Pipeline
  • Bispecific Anti-VEGF-R Antibody Pipeline
Avastin Biosimilar Pipeline:

Marketed VEGF Antibodies in Ophthalmology:
  • Lucentis Sales & Pipeline
  • Eylea Sales & Pipeline
Biosuperior Lucentis & Eylea Pipeline:
  • Anti-VEGF Pipeline in Ophthalmology
  • Bispecific Anti-VEGF and Antibody Combination Pipeline in Ophthalmology
Lucentis Biosimilar Pipeline

3) TNF Antibodies
Tab. 1: Approved and marketed indications of anti-TNF antibodies in regulated markets
Tab. 2: Additional indications of branded anti-TNF antibodies under development 
Tab. 3: 2014 Sales of anti-TNF Antibodies
Marketed TNF Antibodies
Humira Sales & Pipeline
Remicade Sales & Pipeline
Enbrel Sales & Pipeline
Simponi Sales & Pipeline
Cimzia Sales & Pipeline
Biosuperior / Biobetter TNF Antibodies
Biosimilar TNF Antibodies
Humira Biosimilar Antibody Pipeline
Remicade Biosimilar Antibody Pipeline
Enbrel Biosimilar Antibody Pipeline
Cimzia Biosimilar Antibody Pipeline

4) Her2 Antibodies 
Marketed Her2 Antibodies
Herceptin Sales & Pipeline
Perjeta Sales & Pipeline
Kadcyla Sales & Pipeline
Trastuzumab Biosuperiors
Engineered Her2 Antibodies
Bi- and Multispecific Her2 Antibodies
Her2 Antibody-Drug Conjugates
Other Her2 Antibodies
Herceptin Biosimilars

5) CD20 Antibodies 
2014 Sales of CD20 Antibodies
Marketed CD20 Antibodies & Sales
Rituxan/MabThera Pipeline & Sales
Gazyva/ Gazyvaro Pipeline & Sales
Arzerra Pipeline & Sales
Zevalin Pipeline & Sales
Biosuperior CD20 Antibodies
Biosimilar CD20 Antibodies
Rituxan/MabThera (rituximab) Biosimilars

6) EGF-R Antibodies 
2014 Sales of EGF-R Antibodies
Marketed EGF-R Antibodies
Erbitux Sales & Pipeline
Vectibix Sales & Pipeline
Nimotuzumab Pipeline
EGF-R Antibody Biosuperiors
Engineered EGF-R Antibodies
Bi- and Multispecific EGF-R Antibodies
EGF-R Antibody-Drug Conjugates
EGF-R Antibody Biosimilars
Cetuximab Biosimilars

7) RANKL Antibodies
Marketed RANKL Antibodies
Prolia Sales & Pipeline
XGEVA Sales & Pipeline
Ranmark/Pralia Pipeline
Biosuperior RANKL Antibodies
Biosimilar RANKL Antibodies

8) Complement C5 Antibodies
Marketed C5 Antibody Sales & Pipeline
Biosuperior C5 Antibodies
Biosimilar C5 Antibodies

9) Interleukin-12/-23 Antibodies
Marketed IL-12/-23 Antibody Sales & Pipeline

10) Alpha4/Beta1/7 Antibodies
Marketed alpha4/beta1/7 Antibody Sales & Pipeline

11) IgE Antibodies
Marketed IgE Antibody Sales & Pipeline
Biosuperior IgE Antibodies
Biosimilar IgE Antibodies

12) CD80/86 (B7-1/B7-2) Antibodies
Marketed CD80/86 Antibodies Sales & Pipeline
Biosuperior CD80/86 Antibodies
Biosimilar CD80/86 Antibodies

13) Interleukin-6 Receptor (IL-6R) Antibodies
Marketed IL-6R Antibody Sales & Pipeline
Biosuperior IL-6R Antibodies
Biosimilar IL-6R Antibodies

14) Respiratory Syncytial Virus (RSV) Antibodies
Marketed RSV Antibody Sales
Biosuperior RSV Antibodies
Biosimilar RSV Antibodies

15) CD52 Antibodies
Marketed CD52 Antibody Sales 
Biosuperor CD52 Antibodies
Biosimilar CD52 Antibodies

Corporate Therapeutic Antibody Biosimilar & Biosuperior Pipelines

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *